Evidence, Access & Pricing

Evidence Strategy (HEOR)

A dedicated team of subject-matter experts to build the evidence you need, drive medical education, support value-based pricing and gain favorable market access.

Home / Services / Evidence, Access & Pricing / Evidence Strategy (HEOR)

In today’s competitive markets, the challenge is to articulate and quantify the value of a product— and also to differentiate it from competitors and the existing standard of care, to support a strategic price point and to ensure a successful medical communication, market access and reimbursement strategy.  

Trinity’s Evidence Strategy team helps clients to develop a compelling value story, demonstrate must-have evidence and drive scientific dissemination to communicate your product’s value story: 

Develop
  • Disease Landscape and Unbranded Value Story Development
  • Value Drivers and Detractors 
  •  Critical Evidence Review and Gap Assessment 
  •  Evidence Generation Plan and RWE Roadmap 
  • KOL Mapping 
  • Publications Planning 
Demonstrate
Disseminate
  • Publications Planning & Scientific Dissemination (Posters/Manuscripts)
  • PIE (Pre-launch Information Exchange) Deck / AMCP Dossier / Global Value Dossiers
  • Objection Handler

The Evidence Strategy team offers a complete suite of Health Economics and Outcomes Research (HEOR) services to help differentiate the value of a product vs. the competition.  

Leveraging best-in-class, scientifically driven, publication-quality primary and secondary research methods, we help our clients demonstrate the holistic value of their assets across the product lifecycle — from early clinical development all the way to launch and post-launch. 

Explore the Power of a
Strong Value Proposition

Providing the right evidence to payers and other key access stakeholders is essential to unlock the pricing and access potential of therapies. 

Find out more about Trinity’s Value services

  • Evidence-Based Value Arguments

    For HEOR leaders focusing on evidence planning, evidence generation and scientific dissemination, RWE provides a solid foundation that allows them to address their key research questions around the patient, burden of illness and therapy/treatment landscape. The core challenge is two-fold:

    • Pre-launch — demonstrate and measure unmet needs in the current marketplace to pave the way for the upcoming launch
    • Post-launch — articulate the measurable value of an asset and differentiate it to ensure a successful market access and reimbursement strategy
  • Answering Important Business Questions

    Trinity’s integrated RWE and Evidence Strategy teams have collaboratively helped hundreds of clients address their most important business questions:

    • What are the unmet needs in the current treatment paradigm for Disease X?
    • What is the epidemiology of Disease X? Are there sub-types of interest?
    • How do I identify the right patients in the absence of ICD-9 / 10 codes?
    • What is the patient journey for someone suffering from Disease Y?
    • What are the treatment patterns, therapy use, switch / adherence behaviors?
    • What is the comparative effectiveness of therapies in this market / class?
    • What SE and AE are associated with these treatments?
    • What is the overall Healthcare Resource Utilization (HCRU)?
    • What is the holistic cost of care?
    • Strategically, what are the pain points, unmet needs and gaps where Treatment Z can add value?

    Find out more about Trinity EvidenceFirst – Helping clients navigate through the complexities of RWE analysis.

Latest Industry and Scientific Publications

Demand for Real-World Evidence of Medications is Growing

Demand for Real-World Evidence of Medications is Growing

Trinity’s recent white paper, titled Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR, was featured in a recent article by Formulary Watch.

Read now

Systemic Literature Review to Characterize the Burden and Unmet Needs Associated with Cremophor EL

Systemic Literature Review to Characterize the Burden and Unmet Needs Associated with Cremophor EL

Comparing severity and treatment of gout in patients with or without a history of kidney transplantation

Read now

Evaluating Health-Related Quality of Life (HRQoL) in Patients with and without Crohn's Perianal Fistulas (CPF) Using the Euroqol Five-Dimension (EQ-5D-5L) Questionnaire in a Real-World US Setting

Evaluating Health-Related Quality of Life (HRQoL) in Patients with and without Crohn’s Perianal Fistulas (CPF) Using the Euroqol Five-Dimension (EQ-5D-5L) Questionnaire in a Real-World US Setting

Comparing severity and treatment of gout in patients with or without a history of kidney transplantation

Read now

Risk Factors Associated with Recurrence and Corticosteroid-Associated Adverse Events in Patients with Recurrent Pericarditis

Risk Factors Associated with Recurrence and Corticosteroid-Associated Adverse Events in Patients with Recurrent Pericarditis

Comparing severity and treatment of gout in patients with or without a history of kidney transplantation

Read now

Latest Evidence Strategy Intelligence

Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR

Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR

The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. […]

Read now

HTA/Reimbursement Evolution and Priorities for Assessment in a Value-Based Healthcare Environment in Latin America

HTA/Reimbursement Evolution and Priorities for Assessment in a Value-Based Healthcare Environment in Latin America

This session will discuss trends in the HTA/Reimbursement environment in Latin America and the drivers for value-based health care (VBHC) implementation within the region. The potential benefits of VBHC […]

Watch now

France Pilots Opportunity to Increase Speed to Reimbursement for Select Innovative Products

France Pilots Opportunity to Increase Speed to Reimbursement for Select Innovative Products

French president Emmanuel Macron announced a two-year trial that will allow pharmaceutical products that receive an ‘Amélioration du Service Médical Rendu’ (ASMR) rating of IV or better to get reimbursement […]

Read now

The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch

The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch

Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers. In contrast, biosimilar versions of adalimumab have been available in most countries […]

Read now

Our Team

Trinity’s Evidence Strategy team features advanced degrees including multiple PhD-level experts – we consistently deliver high-quality insights and products to meet internal and external stakeholder needs. 

Meet Our Evidence Strategy Experts

The team is led by an Nandini Hadker, an Economist who presents annually at ISPOR, ISPOR-EU, AMCP, AMCP-Nexus and strategic clinical conferences who has authored numerous white papers, academic research posters and peer-reviewed manuscripts in reputed journals.  

Nandini Hadker is supported by two Managing Directors, Matt O’Hara and Jeff Skaar, who are also leaders in the evidence generation and HEOR space and bring deep expertise in the sphere of HEOR, evidence generation and scientific dissemination. 

If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.